Can We Make Cells Young Again?

Five breakthroughs driving the age-reversal revolution

"Reprogramming has a big upside if it can be used safely in people. The technology is still really early, and the potential for catastrophic side effects is high."

In 2006, stem-cell biologist Shinya Yamanaka and his colleagues achieved something that most of the scientific world considered impossible: they transformed ordinary adult skin cells back into a state resembling embryonic stem cells. By introducing just four proteins — now known as the Yamanaka factors (OCT4, SOX2, KLF4, and c-Myc) — they demonstrated that a cell's developmental fate is not fixed. The finding earned Yamanaka the Nobel Prize in Physiology or Medicine in 2012 and launched an entire field.

But complete reprogramming is clinically dangerous: a fully reverted cell loses its specialised identity and risks becoming tumourous. The real longevity opportunity lay in going only partway — briefly applying the reprogramming signal, then withdrawing it before the cell forgets what it is.

Harvard geneticist David Sinclair and colleagues at the Blavatnik Institute have developed the "Information Theory of Ageing." In this framework, DNA is a complete and stable blueprint. Ageing is not the corruption of that blueprint but rather the degradation of the epigenome — the layered system of chemical marks that determines which genes are read in which cells. Over decades, these marks accumulate errors Sinclair calls "epigenetic noise," and cells gradually lose the ability to express the right genes at the right times.

To test this, Sinclair's lab created the "ICE" mouse — a model in which DNA breaks could be induced on demand, rapidly producing epigenetic ageing without altering the underlying DNA sequence. This confirmed that epigenetic disruption alone is sufficient to drive the ageing phenotype.

The direct precursor to the current human trial was work by Yuancheng Ryan Lu — then at the Sinclair Lab, now at the Whitehead Institute — who introduced three Yamanaka factors (excluding c-Myc) into the eyes of ageing mice. The treated animals showed measurable regeneration of retinal ganglion cells and restoration of visual function.

The 2016 Izpisúa Belmonte study at the Salk Institute extended these findings — cyclic expression of Yamanaka factors prolonged lifespan in progeria mouse models and improved regeneration of muscle and pancreatic tissue in normal ageing mice.

The most pressing concern is tumourigenesis. A cell pushed too far toward a stem-like state loses its regulatory brakes — the mechanisms that prevent uncontrolled proliferation. This is precisely why c-Myc, a well-documented oncogene, was removed from the therapeutic combination. The remaining three factors (OSK) have a markedly safer preclinical profile, but their long-term fate in human tissue remains unanswered.

Some researchers advocate for mRNA delivery (which degrades quickly) rather than viral vectors (which can persist), or gene circuits that shut themselves off after a defined period. Tamir Chandra at the Mayo Clinic has noted that when cells lose their identity, known dangers follow.

Despite these concerns, the eye's immune privilege and physical containment make it the most forgiving first environment. Any adverse event stays local and observable rather than cascading systemically — which is why the longevity research community broadly regards the eye as the rational first step.